High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Transl Androl Urol
.
2018 Dec;7(Suppl 6):S738-S740.
doi: 10.21037/tau.2018.08.15.
Authors
Renate Pichler
1
,
Wolfgang Loidl
2
,
Martin Pichler
3
4
Affiliations
1
Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
2
Department of Urology, St Vincent's Hospital of Linz, Linz, Austria.
3
Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria.
4
Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
PMID:
30687612
PMCID:
PMC6323287
DOI:
10.21037/tau.2018.08.15
No abstract available
Publication types
Editorial
Comment